OUR TEAM
WHAT WE DO
PUBLICATIONS

Microbiome innovation for animal health.

BiomEdit is an innovation company that discovers, designs, and develops novel probiotics, microbiome derived bioactives, and engineered microbial medicines to address unmet needs in animal health.

Microbiome innovation for animal health.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.

20% of farm animal productivity is lost to disease

We need new tools to keep animals healthy in a sustainable and environmentally responsible way.

Our ambition is to create solutions to some of the most important problems in animal agriculture and food security by leveraging the potential of the microbiome.

Meet the BiomEdit team

The BiomEdit team is a diverse and balanced mix of both experienced executives and new talent. This includes 20 PhD scientists occupying positions in Discovery, Development, Analytics, Regulatory, and Marketing. Collectively, the team has over 200 peer-reviewed publications and almost 50 patents, and 30% of us have experience taking a new product to market.

Aaron Schacht
CEO
Connect
Arvind Kumar
VP Discovery
Connect
Nathan Augspurger
VP Development
Connect
Emily Helmes
VP Regulatory
Connect
Samantha Steelman
Sr. Director Marketing and Commercialization
Connect
Eric Bonabeau
Chief Technology Officer
Connect
Our platform is based on samples of microbial populations collected from a large number of animals.

These samples represent what the microbiome looks like in healthy, diseased, and dysbiotic states. These populations are then characterized at the genomic, transcriptomic, and metabolomic levels to generate a microbial atlas for each animal species: a comprehensive dataset describing what bacteria are present, how abundant they are, and what functions they perform within that ecosystem.

Microbial atlases provide us with a wealth of resources to draw from and allow us to identify novel candidate probiotic species with unique functions and properties. Rather than being limited to the chance discovery of a bacterial strain with beneficial effects, we are able to selectively identify strains with desired characteristics. We also use a similar approach to the discovery of bioactive microbial metabolites and peptides. In some applications, new probiotic species are then engineered to produce proteins that can direct the immune response, similarly to a vaccine or an anti-toxin.

Our discovery platform  generates three different types of products: probiotics, bioactive compounds, and engineered microbial medicines.

Recent publications from our team

Recombinant Limosilactobacillus (Lactobacillus) delivering nanobodies against Clostridium perfringens NetB and alpha toxin confers potential protection from necrotic enteritis.

Read more

Growth promotion and antibiotic induced metabolic shifts in the chicken gut microbiome.

Read more

Multi-Omics Characterization of Host-Derived Bacillus spp. Probiotics for Improved Growth Performance in Poultry.

Read more
Our investors and supporters

Microbiome innovation for animal health

LinkedIn
© 2022 · All rights reserved
Legal

Microbiome innovation for animal health.

BiomEdit is an innovation company that discovers, designs, and develops novel probiotics, microbiome derived bioactives, and engineered microbial medicines to address unmet needs in animal health.

Microbiome innovation for animal health.

BiomEdit is an innovation company that discovers, designs, and develops novel probiotics, microbiome derived bioactives, and engineered microbial medicines to address unmet needs in animal health.

20% of farm animal productivity is lost to disease

We need new tools to keep animals healthy in a sustainable and environmentally responsible way.Our ambition is to create solutions to some of the most important problems in animal agriculture and food security by leveraging the potential of the microbiome.

Meet the BiomEdit team

The BiomEdit team is a diverse and balanced mix of both experienced executives and new talent. This includes 20 PhD scientists occupying positions in Discovery, Development, Analytics, Regulatory, and Marketing. Collectively, the team has over 200 peer-reviewed publications and almost 50 patents, and 30% of us have experience taking a new product to market.

Meet the BiomEdit team

The BiomEdit team is a diverse and balanced mix of both experienced executives and new talent. This includes 20 PhD scientists occupying positions in Discovery, Development, Analytics, Regulatory, and Marketing. Collectively, the team has over 200 peer-reviewed publications and almost 50 patents, and 30% of us have experience taking a new product to market.

Aaron Schacht
CEO
Connect
Arvind Kumar
VP Discovery
Connect
Nathan Augspurger
VP Development
Connect
Emily Helmes
VP Regulatory
Connect
Samantha Steelman
Sr Director Marketing and Commercialization
Connect
Eric Bonabeau
Chief Technology Office
Connect
Our platform is based on samples of microbial populations collected from a large number of animals.

These samples represent what the microbiome looks like in healthy, diseased, and dysbiotic states. These populations are then characterized at the genomic, transcriptomic, and metabolomic levels to generate a microbial atlas for each animal species: a comprehensive dataset describing what bacteria are present, how abundant they are, and what functions they perform within that ecosystem.Microbial atlases provide us with a wealth of resources to draw from and allow us to identify novel candidate probiotic species with unique functions and properties. Rather than being limited to the chance discovery of a bacterial strain with beneficial effects, we are able to selectively identify strains with desired characteristics. We also use a similar approach to the discovery of bioactive microbial metabolites and peptides. In some applications, new probiotic species are then engineered to produce proteins that can direct the immune response, similarly to a vaccine or an anti-toxin.

Our discovery platform generates three different types of products: probiotics, bioactive compounds, and engineered microbial medicines.

Recent publications from our team

Recombinant Limosilactobacillus (Lactobacillus) delivering nanobodies against Clostridium perfringens NetB and alpha toxin confers potential protection from necrotic enteritis.

Read more

Growth promotion and antibiotic induced metabolic shifts in the chicken gut microbiome.

Read more

Multi-Omics Characterization of Host-Derived Bacillus spp. Probiotics for Improved Growth Performance in Poultry.

Read more

Recombinant Limosilactobacillus (Lactobacillus) delivering nanobodies against Clostridium perfringens NetB and alpha toxin confers potential protection from necrotic enteritis.

Read more

Growth promotion and antibiotic induced metabolic shifts in the chicken gut microbiome.

Read more

Multi-Omics Characterization of Host-Derived Bacillus spp. Probiotics for Improved Growth Performance in Poultry.

Read more
Our investors and supporters

Microbiome innovation for
animal health

LinkedIn
© 2022 · All rights reserved
Legal

Microbiome innovation for animal health.

BiomEdit is an innovation company that discovers, designs, and develops novel probiotics, microbiome derived bioactives, and engineered microbial medicines to address unmet needs in animal health.

20% of farm animal productivity is lost to disease

We need new tools to keep animals healthy in a sustainable and environmentally responsible way.

Our ambition is to create solutions to some of the most important problems in animal agriculture and food security by leveraging the potential of the microbiome.

Meet the BiomEdit team

The BiomEdit team is a diverse and balanced mix of both experienced executives and new talent. This includes 20 PhD scientists occupying positions in Discovery, Development, Analytics, Regulatory, and Marketing. Collectively, the team has over 200 peer-reviewed publications and almost 50 patents, and 30% of us have experience taking a new product to market.

Aaron Schacht
CEO
Connect
Arvind Kumar
VP Discovery
Connect
Nathan Augspurger
VP Development
Connect
Emily Helmes
VP Regulatory
Connect
Samantha Steelman
Senior Director Marketing and Commercialization
Connect
Eric Bonabeau
Chief Technology Office
Connect
Our platform is based on samples of microbial populations collected from a large number of animals.

These samples represent what the microbiome looks like in healthy, diseased, and dysbiotic states. These populations are then characterized at the genomic, transcriptomic, and metabolomic levels to generate a microbial atlas for each animal species: a comprehensive dataset describing what bacteria are present, how abundant they are, and what functions they perform within that ecosystem.

Microbial atlases provide us with a wealth of resources to draw from and allow us to identify novel candidate probiotic species with unique functions and properties. Rather than being limited to the chance discovery of a bacterial strain with beneficial effects, we are able to selectively identify strains with desired characteristics. We also use a similar approach to the discovery of bioactive microbial metabolites and peptides. In some applications, new probiotic species are then engineered to produce proteins that can direct the immune response, similarly to a vaccine or an anti-toxin.

Our discovery platform generates three different types of products: probiotics, bioactive compounds, and engineered microbial medicines.

Recombinant Limosilactobacillus (Lactobacillus) delivering nanobodies against Clostridium perfringens NetB and alpha toxin confers potential protection from necrotic enteritis.

Read more

Growth promotion and antibiotic induced metabolic shifts in the chicken gut microbiome.

Read more

Multi-Omics Characterization of Host-Derived Bacillus spp. Probiotics for Improved Growth Performance in Poultry.

Read more
Our investors and supporters

Microbiome innovation for
animal health

LinkedIn